Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In Reply Dr Keller correctly cites the Food and Drug Administration safety communication regarding the 80-mg dose of simvastatin as a factor that may have influenced the prescribing of that agent relative to Lipitor (atorvastatin calcium; Pfizer Inc). The June 8, 2011, safety communication was preceded by an earlier notice on March 19, 2010, regarding the possibility that 80-mg simvastatin was associated with an increased risk of muscle injury relative to other drugs in the statin class. However, in the years leading up to these safety communications during which less-expensive generic simvastatin products were available (ie, 2007-2009), Lipitor was not only the most commonly prescribed statin, surpassing generic simvastatin, but also the most commonly prescribed drug, surpassing all other prescription drugs.1
Alldredge BK, Kayser SR. Why Physicians Favored Lipitor Over Simvastatin—Reply. JAMA Intern Med. 2013;173(15):1473. doi:10.1001/jamainternmed.2013.7701